Another interesting approach, presented by Zhao et al. [159], implies that novel therapeutics should encompass not only adiponectin signaling but also other adipokines, e.g., leptin, which are also dysregulated in obesity and CVD. Here, ADIPOQ is linked to obesity disorder.